AN OPEN-LABEL EXTENSION STUDY OF XEN496 IN PEDIATRIC SUBJECTS WITH KCNQ2 DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY

Registry ID

XPF-009-302

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

XENON PHARMACEUTICALS INC

Start date

2023-05-08

Last update

2021-10-18

Conditions

• EPILEPSY

Related clinical trials

• A PHASE 3, OPEN-LABEL STUDY TO INVESTIGATE THE LONG-TERM SAFETY AND EFFICACY OF LP352 IN THE TREATMENT OF SEIZURES IN CHILDREN AND ADULTS WITH DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF LP352 IN THE TREATMENT OF SEIZURES IN CHILDREN AND ADULTS WITH DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES
• FERUMOXYTOL ENHANCED HIPPOCAMPAL VASCULAR IMAGING IN EPILEPSY
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF XEN1101 AS ADJUNCTIVE THERAPY IN PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
• FLUNARIZINE FOR TREATMENT RESISTANT ABSENCE EPILEPSY
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY

View on source registry